Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non‐cross‐resistant anthracycline annamycin incorporated in liposomes
- 29 May 1995
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 61 (5) , 666-671
- https://doi.org/10.1002/ijc.2910610513
Abstract
Annamycin (Ann) is a non‐cross‐resistant lipophilic anthracy‐cline antibiotic optimally suited for liposome delivery. We studied how vesicle size and presence of phospholipids with a high phase transition temperature and monosialoganglioside (GM1) in the liposome bilayers affect the pharmacokinetics, tumor selectivity and toxicity of Ann. Entrapment of Ann in multilamellar vesicles (L‐Ann) resulted in a 20% lower heart AUC and a 30–40% higher tumor and liver AUC. Reduction of the liposome size from 1.6 to 0.03 μm increased Ann plasma circulation time and tumor AUC by 2‐fold, enhanced Ann tumor selectivity and decreased Ann subacute toxicity by 2‐fold. The presence of phospholipids with a high phase transition temperature and GM1 in the liposome bilayers further prolonged Ann plasma circulation time by 2‐ to 4‐fold, did not increase Ann tumor AUC and moderately increased Ann subacute toxicity. The anti‐tumor activity of Ann correlated with the tumor AUC achieved with each particular formulation. Our results strongly suggest that vesicle size may be an important determinant of the therapeutic index of liposomal Ann, but they fail to demonstrate a beneficial tumor‐targeting effect of liposomes composed of GM1 and phospholipids with a high phase transition temperature, as has been reported for the hydrophilic parent compound doxorubicin. © 1995 Wiley‐Liss, Inc.Keywords
This publication has 11 references indexed in Scilit:
- Quantitative Analysis of the Lipophilic Doxorubicin Analogue Annamycin in Plasma and Tissue Samples by Reversed-Phase ChromatographyJournal of Pharmaceutical Sciences, 1993
- Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and DogsPharmaceutical Research, 1993
- Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomesInternational Journal of Cancer, 1992
- Pharmacokinetics and antitumor activity of epirubicin encapsulated in long‐circulating liposomes incorporating a polyethylene glycol‐derivatized phospholipidInternational Journal of Cancer, 1992
- The role of surface charge and hydrophilic groups on liposome clearance in vivoBiochimica et Biophysica Acta (BBA) - Biomembranes, 1992
- Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.Proceedings of the National Academy of Sciences, 1991
- Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation timesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1991
- Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivoBiochimica et Biophysica Acta (BBA) - Biomembranes, 1991
- Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomesFEBS Letters, 1990
- Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.Proceedings of the National Academy of Sciences, 1988